203 related articles for article (PubMed ID: 18161149)
1. [New bone density conservation agents for osteoporosis under research and development: Anti-RANKL antibody].
Wada S; Fukawa T; Kamiya S
Nihon Rinsho; 2007 Nov; 65 Suppl 9():459-62. PubMed ID: 18161149
[No Abstract] [Full Text] [Related]
2. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
3. Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
Tankó LB
Curr Opin Investig Drugs; 2007 Oct; 8(10):830-5. PubMed ID: 17907059
[TBL] [Abstract][Full Text] [Related]
4. Treatment of osteoporosis with denosumab.
Lewiecki EM
Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
[TBL] [Abstract][Full Text] [Related]
5. [Control of bone resorption by RANKL-RANK system].
Harada S; Takahashi N
Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
[TBL] [Abstract][Full Text] [Related]
6. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases.
Delmas PD
J Clin Densitom; 2008; 11(2):325-38. PubMed ID: 18375161
[TBL] [Abstract][Full Text] [Related]
7. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Bruhn C
Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
[TBL] [Abstract][Full Text] [Related]
8. [Osteoporosis and RANKL signal].
Nakamura M; Udagawa N
Clin Calcium; 2011 Aug; 21(8):1149-55. PubMed ID: 21814019
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
Lipton A; Goessl C
Bone; 2011 Jan; 48(1):96-9. PubMed ID: 20950721
[TBL] [Abstract][Full Text] [Related]
10. [A new treatment for osteoporosis using fully human monoclonal antibody to RANKL, AMG 162].
Takahashi N; Ozawa H
Clin Calcium; 2005 Jan; 15(1):43-8. PubMed ID: 15632472
[TBL] [Abstract][Full Text] [Related]
11. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
12. [Anti-RANKL monoclonal antibody Denosumab (AMG162)].
Sugimoto T
Clin Calcium; 2011 Jan; 21(1):46-51. PubMed ID: 21187593
[TBL] [Abstract][Full Text] [Related]
13. Study shows that a new type of osteoporosis drug reduces fracture risk.
Harv Womens Health Watch; 2009 Oct; 17(2):6-7. PubMed ID: 19998553
[No Abstract] [Full Text] [Related]
14. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
15. [New mechanism of action RANKL-antibodies reduce bone loss].
Kreutzkamp B
Med Monatsschr Pharm; 2006 Nov; 29(11):425-6. PubMed ID: 17131695
[No Abstract] [Full Text] [Related]
16. Denosumab update.
Lewiecki EM
Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
[TBL] [Abstract][Full Text] [Related]
17. The RANKL pathway and denosumab.
Dore RK
Rheum Dis Clin North Am; 2011 Aug; 37(3):433-52, vi-vii. PubMed ID: 22023901
[TBL] [Abstract][Full Text] [Related]
18. [Osteoporosis treatment by anti-RANKL antibody].
Sugimoto T
Clin Calcium; 2011 Aug; 21(8):1209-15. PubMed ID: 21814027
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
Lewiecki EM
Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
[TBL] [Abstract][Full Text] [Related]
20. Osteoporosis treatment options expand.
Mayo Clin Health Lett; 2010 Nov; 28(11):4. PubMed ID: 21158019
[No Abstract] [Full Text] [Related]
[Next] [New Search]
